medigraphic.com
Instituto Nacional de Salud Pública

2003, Number S3

<< Back Next >>

salud publica mex 2003; 45 (S3)

Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer

García-Carrancá A

Language: English
References: 29
Page: 437-442
PDF size: 83.01 Kb.


ABSTRACT

Today, “persistent” infections by certain types of human papillomavirus (HPV) are considered necessary for developing cervical cancer. Producing efficient vaccines against these viruses may eventually lead to a great reduction in incidence and mortality rates of this cancer. In the case of HPV, the production of traditional vaccines usually based in dead or attenuated viruses is not possible due in part to the lack of systems where large quantities of viral particles could be obtained. Fortunately, the expression of the late L1 protein alone, or in combination with L2, leads to the generation of structures resembling true virions that have been called virus-like particles (VLPs) and constitute excellent candidates as prophylactic vaccines. VLPs have shown to be very immunogenic, and have prevented development of natural or challenged infections in both animal systems and humans. Recently, HPV16 VLPs were shown to be very efficient to prevent the development of “persistent” infections, as determined by PCR assays, in a large group of vaccinated women. Therapeutic vaccines, on the other hand, are expected to have an impact on advanced lesions and residual illness, by taking advantaje of the fact that early E6 and E7 genes are thought to be constitutively expressed in cervical tumors and precursor lesions. Finally, DNA-based vaccines could represent a useful alternative for preventing infections by genital HPV


REFERENCES

  1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002. 2:342-350.

  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189:12-19.

  3. Frazer IH. Vaccines for papillomavirus infection. Virus Res. 2002. 89:271-274.

  4. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles . Virology. 1991. 185:251-257.

  5. Ault KA. Virus-like particles as a potential vaccine for human papillomavirus. Papillomavirus Rep. 2003;14:47-51.

  6. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995. 92:11553-11557.

  7. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh- Desmarquet C et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.

  8. Kirnbauer R, Chandrachud LM, O’Neil BW, Wagner ER, Grindlay GJ, Armstrong A et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996. 219:37-44.

  9. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particule vaccine. J Natl Cancer Inst 2001; 93:284-292.

  10. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-93.

  11. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase 1 study of a recombinant viruslike particule vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183:1485-1493.

  12. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.

  13. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77:1551-1563.

  14. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-1527.

  15. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-3416.

  16. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998. 4:2103-2109.

  17. de Jong A, O’Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-3464 .

  18. van der Burg SH, Kwappenberg KM, O’Neill T, Brandt RM, Melief CJ, Hickling JK et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001;19:3652-3660.

  19. Mendoza L, BubenikJ, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003;23:243-247.

  20. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J et al. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.

  21. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Muller M et al. Chimeric papillomavirus virus-like particles induce a murine selfantigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 1999;73:145-152.

  22. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-3227.

  23. Berumen J, Casas L, Segura E, Amezcua JL, García-Carrancá A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int J Cancer 1994; 56:640-645.

  24. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis.EMBO J. 1997. 16:504-514.

  25. Demeret C, García-Carrancá A, Thierry F. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 2003;22:168-175.

  26. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.

  27. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology 2000;43:331-338.

  28. Rocha-Zavaleta L, Alejandre J, García-Carrancá A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002;66:86-95.

  29. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89:285-293.




2020     |     www.medigraphic.com